ArticleSchizophrenia bulletin2014
Schizophrenia--time to commit to policy change.
Article in Schizophrenia bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Deciphering the shared genetic architecture between schizophrenia and suicide attempt: a statistical genomic study.BMC psychiatry · 2026Pooled it
- Trajectory of efficacy and safety across ulotaront dose levels in schizophrenia: a systematic review and dose-response meta-analysis.The international journal of neuropsychopharmacology · 2025Pooled it
- Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Investigating the shared genetic architecture between schizophrenia and body mass index.Molecular psychiatry · 2023Pooled it
- Trial-Based Economic Evaluations of Supported Employment for Adults with Severe Mental Illness: A Systematic Review.Administration and policy in mental health · 2022Pooled it
- Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials.JAMA psychiatry · 2021Pooled it
- EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Community-based psychosocial interventions for people with schizophrenia in low and middle-income countries: systematic review and meta-analysis.BMC psychiatry · 2017Pooled it
- Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia.Actas espanolas de psiquiatria · 2025Trial
- The internalized stigma, self-efficacy, occupational competence and employment outcome among persons with severe mental illness under one-to-one peer support services in Taiwan.BMC psychiatry · 2025Trial
- Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China.BMC psychiatry · 2025Trial
- The Effect of Accelerated Continuous Theta Burst Stimulation on Weight Loss in Overweight Individuals With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.Schizophrenia bulletin · 2024Trial
- The effect of continuous theta burst stimulation on antipsychotic-induced weight gain in first-episode drug-naive individuals with schizophrenia: a double-blind, randomized, sham-controlled feasibility trial.Translational psychiatry · 2024Trial
- Predictors and moderators of burden of care and emotional distress in first-episode psychosis caregivers: results from the GET UP pragmatic cluster randomised controlled trial.Epidemiology and psychiatric sciences · 2019Trial
- Social Recovery Therapy in improving activity and social outcomes in early psychosis: Current evidence and longer term outcomes.Schizophrenia research · 2019Trial
- Improving Weight in People with Serious Mental Illness: The Effectiveness of Computerized Services with Peer Coaches.Journal of general internal medicine · 2017Trial
- Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.The international journal of neuropsychopharmacology · 2016Trial
- Functional variants at 1p36.23 confer risk of schizophrenia through modulating RERE.Nature communications · 2026Article
- Prevalence and influencing factors associated with the risk of malnutrition among long-term inpatients with schizophrenia in China.Frontiers in psychiatry · 2026Article
- Assessing directional connections between symptoms, cognition, insight, and real-life functioning in schizophrenia: a partial ancestor graphs analysis.Frontiers in psychiatry · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Care and outcomes for people with schizophrenia have improved in recent years, but further progress is needed to help more individuals achieve an independent and fulfilled life. This report sets out the current need, informs policy makers and all relevant stakeholders who influence care quality, and supports their commitment to creating a better future. The authors recommend the following policy actions, based on research evidence, stakeholder consultation, and examples of best practice worldwide. (1) Provide an evidence-based, integrated care package for people with schizophrenia that addresses their mental and physical health needs. (2) Provide support for people with schizophrenia to enter and to remain in their community, and develop mechanisms to help guide them through the complex benefit and employment systems. (3) Provide concrete support, information, and educational programs to families and carers on how to enhance care for an individual living with schizophrenia in a manner that entails minimal disruption to their lives. (4) All stakeholders, including organizations that support people living with schizophrenia, should be consulted to regularly revise, update, and improve policy on the management of schizophrenia. (5) Provide support, which is proportionate to the impact of the disease, for research and development of new treatments. (6) Establish adequately funded, ongoing, and regular awareness-raising campaigns that form an integral part of routine plans of action. Implementation of the above recommendations will require engagement by every stakeholder, but with commitment from all, change can be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.